Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefpirome clinical pharmacokinetics

L C Strenkoski1, D E Nix

  • 1Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, New York.

Clinical Pharmacokinetics
|October 1, 1993
PubMed
Summary

Cefpirome, a novel cephalosporin, shows strong efficacy against Gram-positive bacteria and good potency against Gram-negative bacteria. Its unique structure enhances beta-lactamase stability and tissue penetration, typical pharmacokinetic properties, and favorable dosing for clinical effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions.

The Annals of pharmacotherapy·2001
Same author

Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.

Pharmacotherapy·2001
Same author

In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.

Diagnostic microbiology and infectious disease·2001
Same author

Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.

Antimicrobial agents and chemotherapy·2001
Same author

Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.

The Journal of trauma·2000
Same author

Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·1999

Area of Science:

  • Microbiology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Cefpirome is a new cephalosporin antibiotic.
  • It possesses enhanced activity against Gram-positive organisms compared to ceftazidime.
  • Structural modifications from cefotaxime improve beta-lactamase stability and bacterial membrane penetration.

Purpose of the Study:

  • To evaluate the in vitro potency and pharmacokinetic profile of cefpirome.
  • To assess the tissue penetration and elimination characteristics of cefpirome.
  • To determine the optimal dosage regimen based on pharmacodynamic parameters.

Main Methods:

  • In vitro susceptibility testing against Gram-negative and Gram-positive organisms.
  • Pharmacokinetic studies including bioavailability, protein binding, volume of distribution, and elimination half-life.
  • Tissue fluid concentration measurements (prostate, lung, CSF, etc.).
  • Analysis of renal elimination and creatinine clearance correlation.

Main Results:

  • Cefpirome demonstrates potent in vitro activity against Gram-positive and Gram-negative bacteria.
  • High bioavailability (>90%) after intramuscular injection and low protein binding (~10%).
  • Good penetration into various tissues and body fluids, with an elimination half-life of approximately 2 hours.
  • Renal excretion of unchanged drug accounts for ~80% of the dose.

Conclusions:

  • Cefpirome's structural features contribute to its enhanced antimicrobial spectrum and stability.
  • Its pharmacokinetic profile supports typical cephalosporin administration routes and dosing intervals.
  • Therapeutic concentrations are achieved in relevant tissues, supporting its clinical utility.
  • A dosage of 2g every 12 hours maintains concentrations above MIC for susceptible pathogens in patients without renal impairment.

Related Experiment Videos